SK Biopharmaceuticals Deploys Global Experts to Strengthen End-to-End R&D
Strengthening Leadership in Neuroscience and Oncology R&D
Deployment of Eight MDs in Clinical Development, PV, and MA
Expanding the Foundation for Creating Next-Generation Global New Drugs
SK Biopharmaceuticals has deployed global experts throughout the entire research and development (R&D) process, from the discovery of novel drug candidates to clinical development. The company’s strategy is to strengthen its leadership in neuroscience and oncology research while accelerating the discovery of subsequent global new drugs by recruiting clinical experts with medical doctor (MD) backgrounds, particularly through its U.S. subsidiary.
On September 8, SK Biopharmaceuticals announced that it has successively enhanced its neuroscience leadership at the drug discovery stage and its oncology clinical development leadership at the development stage. The company has built specialized leadership by field, focusing on radiopharmaceuticals (RPT) and targeted protein degradation (TPD), and has assigned MDs even at the development stage.
Recently, SK Biopharmaceuticals reorganized its existing central nervous system (CNS) research functions into the “Neuroscience Division,” placing it directly under the CEO, and recruited global neuroscience R&D expert Taeho Kim, Ph.D., as the head of the division.
Dr. Kim has participated in neuroscience drug research and development for over 20 years, including 12 years at Novartis, where he was responsible for novel drug discovery, preclinical and early clinical development, and portfolio strategy in the neuroscience field. He will oversee SK Biopharmaceuticals’ Neuroscience Division, promote the discovery of next-generation pipelines, drive open innovation, and lead joint research efforts both domestically and internationally.
In oncology, the company is also expanding next-generation pipeline discovery by building specialized leadership in RPT and TPD. In the RPT field, RPT Center Director Yongje Shin is leading candidate discovery and the establishment of the company’s proprietary chelator platform. The company is also working to secure a supply chain for radioisotopes and expand new pipelines. In the TPD area, research is led by Ryan Kruger, Ph.D., Chief Scientific Officer (CSO) of SK Life Science Labs, the U.S. subsidiary. Leveraging his expertise in cancer biology and epigenetics, Dr. Kruger is spearheading research on next-generation anticancer drugs using targeted protein degradation technology.
At the development stage, MDs are leading global clinical development efforts, centered on Chief Medical Officer (CMO) Sunita Misra, a pediatric neurologist, epilepsy specialist, and physician-scientist. Approximately 20% of the core development and medical functional personnel have MD backgrounds. In July, the company brought on Suyeon Kim, M.D. (Vice President), a physician-scientist with over 18 years of experience at global pharmaceutical firms such as Bristol Myers Squibb and AbbVie. SK Biopharmaceuticals ensures that MDs with hands-on clinical and prescribing experience help incorporate clinical value and unmet medical needs into R&D strategies right from the early stages of development.
In the CNS field, clinical development is underway for major programs such as primary generalized tonic-clonic (PGTC) seizures, partial seizures and pediatric indication expansion, and carisbamate. In oncology, MDs are also participating in programs such as p300, NTSR1, and CA9. In pharmacovigilance (PV) and medical affairs (MA), they are responsible for safety assessment and management, as well as scientific and medical communication with healthcare professionals.
Based on this R&D framework, SK Biopharmaceuticals also plans to accelerate its “East-West Bridge” strategy, connecting promising new drug candidates discovered in Korea and Asia to the global market. The company intends to secure candidates in Asia, conduct preclinical and early clinical studies, and then leverage its global clinical development and commercialization capabilities.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
SK Biopharmaceuticals CEO Donghoon Lee stated, “We will continue to secure global talent with experience and expertise in each field to further strengthen our competitiveness and execution for creating next-generation global new drugs.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.